GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Earnings Yield (Joel Greenblatt) %

Zeo ScientifiX (Zeo ScientifiX) Earnings Yield (Joel Greenblatt) % : 212.77% (As of Jan. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Earnings Yield (Joel Greenblatt) %?

Zeo ScientifiX's Enterprise Value for the quarter that ended in Jan. 2024 was $-474 Mil. Zeo ScientifiX's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was $-1,017 Mil. Zeo ScientifiX's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jan. 2024 was 212.77%.

The historical rank and industry rank for Zeo ScientifiX's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

ZEOX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35036.89   Med: -15.83   Max: 212.77
Current: 212.77

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Zeo ScientifiX was 212.77%. The lowest was -35036.89%. And the median was -15.83%.

ZEOX's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -14.85 vs ZEOX: 212.77

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Zeo ScientifiX's Forward Rate of Return (Yacktman) % for the quarter that ended in Jan. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Zeo ScientifiX Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Zeo ScientifiX's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Earnings Yield (Joel Greenblatt) % Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.48 -8.05 -18.21 -22.68 -55.56

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10,000.00 -10,000.00 -10,000.00 -55.56 212.77

Competitive Comparison of Zeo ScientifiX's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Zeo ScientifiX's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Earnings Yield (Joel Greenblatt) % falls into.



Zeo ScientifiX Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Zeo ScientifiXs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Oct. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-6.555/11.8287596
=-55.42 %

Zeo ScientifiX's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,017 Mil.



Zeo ScientifiX  (OTCPK:ZEOX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Zeo ScientifiX Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140